A detailed history of Epiq Capital Group, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Epiq Capital Group, LLC holds 86,291 shares of ABCL stock, worth $244,203. This represents 0.07% of its overall portfolio holdings.

Number of Shares
86,291
Previous 86,291 -0.0%
Holding current value
$244,203
Previous $255,000 12.55%
% of portfolio
0.07%
Previous 0.09%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

SELL
$9.2 - $13.68 $218,555 - $324,982
-23,756 Reduced 21.59%
86,291 $853,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $10.65 $107,804 - $200,720
18,847 Added 20.67%
110,047 $1.17 Million
Q1 2022

May 13, 2022

SELL
$7.46 - $14.14 $8,638 - $16,374
-1,158 Reduced 1.25%
91,200 $889,000
Q4 2021

Feb 09, 2022

SELL
$12.99 - $17.73 $657,449 - $897,350
-50,612 Reduced 35.4%
92,358 $1.32 Million
Q3 2021

Nov 12, 2021

BUY
$14.85 - $21.34 $2.12 Million - $3.05 Million
142,970 New
142,970 $2.87 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $807M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Epiq Capital Group, LLC Portfolio

Follow Epiq Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Epiq Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Epiq Capital Group, LLC with notifications on news.